- All
- Important
- Financial Update
- Fund Raise
- Board Meeting
- Dividend/Bonus
- JV/Acquisition
- Investor Meet
- Insider Trade
- Pledging
- Others
Loading...
Incorporated in 1993, Medicamen Biotech Ltd is a research-led pharmaceutical company involved in developing, manufacturing, and marketing generic finished dosage formulations, and Oncology Formulations
Medicamen Biotech's FY26 saw consolidated revenue grow 21.66% to ₹197.77 Cr, with PAT jumping 49.43% to ₹9.80 Cr. Domestic sales surged 71% via Medicamen Life Sciences. Key developments include international expansion, CDMO wins, and oncology division growth. The company incurred ₹1.18 Lakh in fines for compliance issues.
Medicamen Biotech reported FY26 turnover of ~178.85 Cr & PAT of ~9.41 Cr, with 80% sales from global markets. The company boosted R&D/Capex for sustainability and increased MSME sourcing. A `7,080 fine for a minor filing delay was noted and resolved. Loans to related parties significantly increased.